Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28396885 | 0.92 | RAB9A (0.62) | RAB9ANPC1KDM4ECGASALDH1A1 | |
| SCHEMBL7233460 | 0.91 | SMN1; SMN2 (0.52) | RAB9ANPC1KDM4ELMNAALB | |
| SCHEMBL14889096 | 0.89 | GAA (0.56) | RAB9ANPC1KDM4EHSD17B10CGAS | |
| SCHEMBL7241456 | 0.88 | GABRA1 (0.49) | KDM4EGABRA1GABRB2HSD17B10LMNA | |
| SCHEMBL14889093 | 0.86 | RAB9A (0.46) | RAB9ANPC1KDM4EHSD17B10CGAS | |
| SCHEMBL5630676 | 0.86 | GABRA1 (0.72) | RAB9ANPC1KDM4EGABRA1GABRB2 | |
| SCHEMBL1691295 | 0.85 | SMN1; SMN2 (0.51) | RAB9ANPC1KDM4EGABRA1GABRB2 | |
| SCHEMBL1761287 | 0.82 | GABRA1 (0.74) | RAB9ANPC1KDM4EGABRA1GABRB2 | |
| SCHEMBL7558746 | 0.82 | KDM4E (0.45) | RAB9ANPC1KDM4EHSD17B10CGAS | |
| SCHEMBL7240481 | 0.81 | ALOX5 (0.48) | RAB9ANPC1KDM4EGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | NEUROGEN CORPORATION | 2002-03-14 | — | — | US | claimed |
| WO-2002002557-A2 | 2-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES: A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-10 | — | — | WO | claimed |
| EP-2586780-B1 | 2-ARYL IMIDAZO[1,2-A]PYRIDINE-3-ACETAMIDE DERIVATIVES, PREPARATION METHODS AND USE THEREOF | INST PHARMACOLOGY & TOXICOLOGY ACAD MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2017-03-22 | — | — | EP | disclosed |
| US-8980887-B2 | 2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and uses thereof | INSTITUTE OF PHARMACOLOGY (CN) | 2015-03-17 | — | — | US | disclosed |
| US-20130203754-A1 | 2-Aryl Imidazo[1,2-a]Pyridine-3-Acetamide Derivatives, Preparation Methods and Uses Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2013-08-08 | — | — | US | disclosed |
| EP-2586780-A1 | 2-ARYL IMIDAZO[1,2-A]PYRIDINE-3-ACETAMIDE DERIVATIVES, PREPARATION METHODS AND USE THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2013-05-01 | — | — | EP | disclosed |
| US-6552037-B2 | An imidazo(1,2-a)Pyridine compound useful for altering the signal-transducing activity of gamma-aminobuytric acid receptor | NEUROGEN CORPORATION | 2003-04-22 | — | — | US | disclosed |
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | NEUROGEN CORPORATION | 2002-03-14 | — | — | US | disclosed |
| WO-2002002557-A2 | 2-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES: A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203754-A1 | 2-Aryl Imidazo[1,2-a]Pyridine-3-Acetamide Derivatives, Preparation Methods and Uses Thereof | TSPO, SLC6A1, TBXA2R | RAB9A 2262/4885NPC1 780/4885KDM4E 3821/4885 |
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | GABBR2, GABRP, GABBR1 | RAB9A 2092/4885NPC1 941/4885KDM4E 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.